Zevra Therapeutics, Inc. (FRA:1GDA)

Zevra Therapeutics Statistics

Total Valuation

FRA:1GDA has a market cap or net worth of EUR 403.88 million. The enterprise value is 286.21 million.

Market Cap	403.88M
Enterprise Value	286.21M

Important Dates

The next estimated earnings date is Friday, March 6, 2026.

Earnings Date	Mar 6, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	56.30M
Shares Outstanding	n/a
Shares Change (YoY)	+31.47%
Shares Change (QoQ)	-0.66%
Owned by Insiders (%)	0.86%
Owned by Institutions (%)	65.39%
Float	52.33M

Valuation Ratios

The trailing PE ratio is 15.79 and the forward PE ratio is 17.01.

PE Ratio	15.79
Forward PE	17.01
PS Ratio	5.62
PB Ratio	3.56
P/TBV Ratio	3.89
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	11.19
EV / Sales	3.94
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-13.86

Financial Position

The company has a current ratio of 8.62, with a Debt / Equity ratio of 0.47.

Current Ratio	8.62
Quick Ratio	8.29
Debt / Equity	0.47
Debt / EBITDA	n/a
Debt / FCF	-2.59
Interest Coverage	-3.52

Financial Efficiency

Return on equity (ROE) is 34.81% and return on invested capital (ROIC) is -11.12%.

Return on Equity (ROE)	34.81%
Return on Assets (ROA)	-7.84%
Return on Invested Capital (ROIC)	-11.12%
Return on Capital Employed (ROCE)	-11.87%
Revenue Per Employee	1.22M
Profits Per Employee	433,604
Employee Count	59
Asset Turnover	0.37
Inventory Turnover	n/a

Taxes

In the past 12 months, FRA:1GDA has paid 15.61 million in taxes.

Income Tax	15.61M
Effective Tax Rate	34.15%

Stock Price Statistics

The stock price has decreased by -14.69% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-14.69%
50-Day Moving Average	8.36
200-Day Moving Average	7.87
Relative Strength Index (RSI)	43.09
Average Volume (20 Days)	107

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	4.10

Income Statement

In the last 12 months, FRA:1GDA had revenue of EUR 71.92 million and earned 25.58 million in profits. Earnings per share was 0.46.

Revenue	71.92M
Gross Profit	58.01M
Operating Income	-24.69M
Pretax Income	45.72M
Net Income	25.58M
EBITDA	-20.13M
EBIT	-24.69M
Earnings Per Share (EPS)	0.46

Balance Sheet

The company has 170.04 million in cash and 53.45 million in debt, giving a net cash position of 116.59 million.

Cash & Cash Equivalents	170.04M
Total Debt	53.45M
Net Cash	116.59M
Net Cash Per Share	n/a
Equity (Book Value)	113.50M
Book Value Per Share	2.02
Working Capital	169.61M

Cash Flow

In the last 12 months, operating cash flow was -19.91 million and capital expenditures -738,092, giving a free cash flow of -20.65 million.

Operating Cash Flow	-19.91M
Capital Expenditures	-738,092
Free Cash Flow	-20.65M
FCF Per Share	n/a

Margins

Gross margin is 80.65%, with operating and profit margins of -34.32% and 41.86%.

Gross Margin	80.65%
Operating Margin	-34.32%
Pretax Margin	63.57%
Profit Margin	41.86%
EBITDA Margin	-27.99%
EBIT Margin	-34.32%
FCF Margin	n/a

Dividends & Yields

FRA:1GDA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-31.47%
Shareholder Yield	-31.47%
Earnings Yield	6.33%
FCF Yield	-5.11%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number
Graham Upside

Stock Splits

The last stock split was on December 28, 2020. It was a reverse split with a ratio of 0.0625.

Last Split Date	Dec 28, 2020
Split Type	Reverse
Split Ratio	0.0625

Scores

FRA:1GDA has an Altman Z-Score of 0.65 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.65
Piotroski F-Score	4